Delcath Systems, HEPZATO KIT
Melphalan word deur die FDA goedgekeur as 'n lewergerigte behandeling vir uveale melanoom
Nov 2023: Die Food and Drug Administration het HEPZATO KIT (melphalan for Injection/Hepatic Delivery System, Delcath Systems, Inc.) goedgekeur as 'n lewergerigte behandeling vir volwasse pasiënte met uveale melanoom wat nie opereerbaar is nie.
Sjina, Kliniese proewe, Hepatosellulêre karsinoom, JW Therapeutics, Sjanghai
JW Therapeutics kondig die aanvang van kliniese studie van JWATM214 aan by pasiënte met gevorderde hepatosellulêre karsinoom
SHANGHAI, CHINA, 28 Februarie 2023 - JW Therapeutics (HKEX: 2126), 'n onafhanklike en innoverende biotegnologiemaatskappy wat fokus op die ontwikkeling, vervaardiging en kommersialisering van sel-immunoterapie-produkte, het die inisiatief aangekondig.
durvaluumab, Hepatosellulêre karsinoom, tremelimumab
Tremelimumab word deur die FDA in kombinasie met durvalumab goedgekeur vir nie-opereerbare hepatosellulêre karsinoom
November 2022: The Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). Efficacy was evaluat..
Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq
Middels goedgekeur vir die behandeling van lewerkanker
Des 2021: Die volgende middels is op datum goedgekeur vir die behandeling van lewerkanker:. Kontroleer asseblief die voorskrifinligting voordat u die geneesmiddel inneem. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-SM..
Leweroorplanting, Leweroorplanting in Apollo Chennai
Lewerkanker chirurgie en oorplanting deur dr Selvakumar
July 14, 2021: Check out interview of Dr. Selvakumar Naganathan - Clinical Lead - Liver transplantation and HPB surgery, Apollo Hospitals, Chennai. Check out the video and also excerpts of the interview. https://www.youtube.com..
Atezolizumab, Bevacizumab, Nuutste dwelms
Atezolizumab plus Bevacizumab vir die behandeling van lewerkanker
13 Julie 2021: 'n Nuwe medikasie beskikbaar vir mense met 'n soort lewerkanker genaamd hepatosellulêre karsinoom, wat beter lyk as standaardterapie (HCC). Die Food and Drug Administration (FDA) het atezoliz goedgekeur.
CABOMETYX, Cabozantinib, Exelixis, FDA, HCC, Hepatosellulêre karsinoom, Sorafenib, USFDA
Cabozantinib is goedgekeur deur die FDA vir hepatosellulêre karsinoom
On January 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) was approved by the Food and Drug Administration for patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. The appr..
Behandeling van lewerkanker in 2023
Las van lewerkanker Lewerkanker is 'n algemene kwaadaardige gewas wat verantwoordelik is vir meer as die helfte van die wêreldwye lewerkanker. Die aanvang van hepatosellulêre karsinoom (HCC) is verborge, en vroeë simptome is nie duidelik nie. Meeste mense ..
Laaste immunoterapie in lewerkankerbehandeling
Liver cancer Liver cancer is currently the fifth most common cause of cancer-related death in the world. The current first-line systemic treatment drug is mainly sorafenib, but usually only prolongs the overall survival of 3 mont..
NK-sel-immunoterapie in gevorderde lewerkankergevalle
Cases of NK cell immunotherapy for advanced liver cancer 92-year-old advanced cancer patient has complete remission Seven years ago, Ms. M, who was in her 80s, was diagnosed with hepatocellular carcinoma (caused by cancer in the p..